HomeACADEMIA
ACADEMIA

Long-Term Safety of PCSK9 Inhibitors Remains to Be Determined: New Atherosclerosis Prevention Guidelines
(Jul.4.2017)

Makoto Kinoshita, chairman of the JAS’s epidemiology and clinical management of atherosclerosis committee
The Japan Atherosclerosis Society (JAS) has issued its guidelines for the prevention of atherosclerotic diseases 2017. Regarding PCSK9 inhibitors, which are novel treatments for dyslipidemia, the guidelines state that “their indications and efficacy have been established, but their long-term safety has not yet been confirmed.” ...
(LOG IN FOR FULL STORY)

News Calendar